Hepatitis C Virus Drug Costs Likely to Fall

The high cost of hepatitis C virus (HCV) drugs has caused significant financial strain for patients and the health care system. These drugs cost as much as $95,000 for a 12-week treatment, but carry a 90% or better cure rate, which many believe justifies the cost.  

While some insurers have implemented cost containment strategies to prevent early stage patients from receiving the treatment, lawsuits have been filed challenging the ethics of these practices.

Lawmakers are now struggling to create legislation that will provide these patients with the treatments they need, but a majority of proposals do not gain traction, according to a report published by Mediware.

Sofosbuvir (Sovaldi) received FDA approval in 2013, and was the first drug deemed safe and effective without interferon. It was also the first approved curative treatment for HCV.

No previous treatments resulted in a sustained virologic response, which made sofosbuvir a highly sought-after drug. Gilead Sciences priced the treatment at $1000 per pill, making the total cost of the treatment $84,000.

Gilead then combined sofosbuvir with a new drug, ledipasvir, to create the even more effective combination treatment, Harvoni. Harvoni’s total treatment cost is $94,500 for a 12-week regimen.

If CDC estimates are correct and 3.5 million Americans have HCV, then treatment with Harvoni would cost payers $331 billion, which was more than total drug spending in 2013, according to the report.

Although most other specialty drugs only treat a small number of patients, HCV drugs treat a large patient population, and provide manufacturers with opportunities to generate significant revenue.

Interestingly, sofosbuvir only costs $900 in Egypt, and $55,000 in Canada, substantially less than the cost in the United States. This has caused some lawmakers to accuse Gilead of price gouging, and limiting access to effective treatments, according to the report.

In some states, Medicaid beneficiaries may not have equal access to the drugs. US Senators have reported that some states cover 9.1% of enrollees for HCV treatment, while others only cover less than 1%.

Medicaid is unable to cover treatment for all enrollees, since covering 1 treatment with Harvoni costs the same as the annual health care costs for 29 enrollees, which highlights the need for lower costs, according to the study.

Both private and public insurers have had to create eligibility requirements that prioritize patients with liver damage, and those who have failed to respond to less costly treatments due to the high price of newer drugs. However, the Department of Veterans Affairs recently announced they would cover HCV treatment costs for all veterans as a result of increased funding and decreased drug costs, according to the report.

With President Donald Trump advocating for lower drug costs, patients with HCV may gain expanded access to treatment.



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.
A Bluetooth-enabled, nanochannel drug delivery system administers controlled doses based on patients’ therapeutic needs.
Research highlights the importance of reaching non-white and younger populations with skin cancer prevention messages.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$